1. Home
  2. LSF vs QTTB Comparison

LSF vs QTTB Comparison

Compare LSF & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Laird Superfood Inc.

LSF

Laird Superfood Inc.

HOLD

Current Price

$2.31

Market Cap

24.3M

ML Signal

HOLD

Logo Q32 Bio Inc. Common Stock

QTTB

Q32 Bio Inc. Common Stock

HOLD

Current Price

$3.46

Market Cap

25.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LSF
QTTB
Founded
2015
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.3M
25.1M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
LSF
QTTB
Price
$2.31
$3.46
Analyst Decision
Strong Buy
Hold
Analyst Count
1
7
Target Price
$12.00
$12.17
AVG Volume (30 Days)
118.3K
8.9M
Earning Date
11-10-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$48,146,862.00
N/A
Revenue This Year
$18.05
N/A
Revenue Next Year
$17.53
N/A
P/E Ratio
N/A
N/A
Revenue Growth
17.73
N/A
52 Week Low
$2.18
$1.35
52 Week High
$8.99
$27.61

Technical Indicators

Market Signals
Indicator
LSF
QTTB
Relative Strength Index (RSI) 28.90 62.78
Support Level $2.18 $3.23
Resistance Level $2.78 $3.96
Average True Range (ATR) 0.19 0.48
MACD 0.05 0.15
Stochastic Oscillator 27.67 35.16

Price Performance

Historical Comparison
LSF
QTTB

About LSF Laird Superfood Inc.

Laird Superfood Inc is engaged in the business of manufacturing and marketing differentiated plant-based and functional foods. The product portfolio includes Coffee creamers, Hydration products and beverage-enhancing supplements, Harvest snacks and various other food items, and Coffee, tea, and hot chocolate products.

About QTTB Q32 Bio Inc. Common Stock

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function.

Share on Social Networks: